- Home
- AMST vs PHGE Comparison
AMST vs PHGE Comparison
Compare AMST & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- PHGE
- Stock Information
- Founded
- AMST 2017
- PHGE 2015
- Country
- AMST United States
- PHGE Israel
- Employees
- AMST 11
- PHGE N/A
- Industry
- AMST Computer Software: Prepackaged Software
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- PHGE Health Care
- Exchange
- AMST Nasdaq
- PHGE Nasdaq
- Market Cap
- AMST 15.7M
- PHGE 12.6M
- IPO Year
- AMST 2020
- PHGE N/A
- Fundamental
- Price
- AMST $3.14
- PHGE $0.49
- Analyst Decision
- AMST
- PHGE Strong Buy
- Analyst Count
- AMST 0
- PHGE 1
- Target Price
- AMST N/A
- PHGE $15.00
- AVG Volume (30 Days)
- AMST 2.1M
- PHGE 316.5K
- Earning Date
- AMST 11-13-2025
- PHGE 11-13-2025
- Dividend Yield
- AMST N/A
- PHGE N/A
- EPS Growth
- AMST N/A
- PHGE N/A
- EPS
- AMST N/A
- PHGE N/A
- Revenue
- AMST $82,544.00
- PHGE N/A
- Revenue This Year
- AMST N/A
- PHGE N/A
- Revenue Next Year
- AMST N/A
- PHGE N/A
- P/E Ratio
- AMST N/A
- PHGE N/A
- Revenue Growth
- AMST N/A
- PHGE N/A
- 52 Week Low
- AMST $2.00
- PHGE $0.34
- 52 Week High
- AMST $6.27
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- AMST 53.57
- PHGE 47.21
- Support Level
- AMST $3.11
- PHGE $0.46
- Resistance Level
- AMST $3.56
- PHGE $0.51
- Average True Range (ATR)
- AMST 0.28
- PHGE 0.03
- MACD
- AMST 0.05
- PHGE -0.01
- Stochastic Oscillator
- AMST 24.77
- PHGE 34.68
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).